Darzalex® is the official global commercial brand name, and Zhaoke is its Chinese brand name developed by Janssen. It is an intravenous fully human anti-CD38 monoclonal antibody. It targets CD38 highly expressed on myeloma plasma cells, exerting multi-mechanism anti-tumor activity…
Sarclisa® is the official global commercial brand name, and Saikeyi is its Chinese brand name developed by Sanofi. It is an intravenous anti-CD38 monoclonal antibody. It binds to CD38 expressed on myeloma cells, triggering multiple tumor-killing mechanisms including antibody-dependent cellular…
Columvi® is the official global commercial brand name, and Gaoluohua is its Chinese brand name developed by Roche. It is a bispecific CD3/CD20 monoclonal antibody for intravenous infusion. It crosslinks CD3-expressing T cells and CD20-positive malignant B cells, activating endogenous…
Kesimpta® is the official global commercial brand name, and Quanxinda is its Chinese brand name developed by Novartis. It is a fully human anti-CD20 monoclonal antibody for subcutaneous self-administration via pre-filled autoinjector. It selectively binds CD20 on mature B lymphocytes…
Gazyva® is the official global commercial brand name, and Jialuohua is its Chinese brand name developed by Roche. It is a humanized anti-CD20 type II monoclonal antibody for intravenous infusion. It induces direct B-cell death and antibody-dependent cellular cytotoxicity, depleting…
TEPMETKO® is the official global commercial brand name, and Tuodekang is its Chinese brand name developed by Merck. It is an oral highly selective MET tyrosine kinase inhibitor. It blocks MET receptor signaling cascade, inhibiting proliferation and metastasis of non-small…
Nexavar® is the official global commercial brand name, and Duojimei is its Chinese brand name developed by Bayer. It is an oral multi-target kinase inhibitor. It simultaneously suppresses Raf serine/threonine kinases and VEGFR/PDGFR tyrosine kinases, inhibiting both tumor cell proliferation…
QINLOCK® is the original global commercial brand name, and Qingle is its Chinese brand name distributed by Zai Lab. It is an oral switch-control type multi-target tyrosine kinase inhibitor. It locks the inactive conformation of KIT and PDGFRα kinases, broadly…
TRUQAP® is the official global commercial brand name, and Kuikedé is its Chinese brand name developed by AstraZeneca. It is an oral pan-AKT kinase inhibitor that blocks AKT-mediated downstream PI3K/AKT signaling, suppressing tumor proliferation driven by PIK3CA, AKT1 or PTEN…
Tabrecta® is the original global commercial brand name, and Tuoruidar is its Chinese brand name developed by Novartis. It is an oral highly selective MET tyrosine kinase inhibitor. It potently blocks MET receptor signaling to inhibit tumor cell proliferation and…